Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04995094 |
| Title | Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma |
| Recruitment | Withdrawn |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | HiberCell, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |